| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06622603 | the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years… | Gout | Recruiting |
| NCT07369622 | HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | Gout Initiating Urate-loweringUrate-lowering Therapy | Not Yet Recruiting |
| Phase 3 | |||
| NCT07414394 | Tigulixostat (IBI128) vs Febuxostat in Gout | Gout | Recruiting |
| Phase 2 | |||
| NCT07362355 | The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the… | Primary Gout and Hyperuricemia | Recruiting |
| NCT07498647 | Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia | Gout and Hyperuricemia | Not Yet Recruiting |
| Not specified | |||
| NCT07326839 | Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT | Gout | Not Yet Recruiting |